HomeInsightsStock Comparison

Aarti Drugs Ltd vs Aarti Pharmalabs Ltd Stock Comparison

Aarti Drugs Ltd vs Aarti Pharmalabs Ltd Stock Comparison

Last Updated on: Sep 11, 2025

Key Highlights

  • The Latest Trading Price of Aarti Drugs Ltd is ₹ 510.85 as of 11 Sep 15:30.
  • The P/E Ratio of Aarti Drugs Ltd changed from 8.3 on March 2020 to 18.5 on March 2025 . This represents a CAGR of 14.29% over 6 yearsThe P/E Ratio of Aarti Pharmalabs Ltd changed from 12.9 on March 2023 to 24.9 on March 2025 . This represents a CAGR of 24.51% over 3 years.
  • The Market Cap of Aarti Drugs Ltd changed from ₹ 1178 crore on March 2020 to ₹ 3123 crore on March 2025 . This represents a CAGR of 17.64% over 6 yearsThe Market Cap of Aarti Pharmalabs Ltd changed from ₹ 2489 crore on March 2023 to ₹ 6784 crore on March 2025 . This represents a CAGR of 39.69% over 3 years.
  • The revenue of Aarti Drugs Ltd for the Jun '25 is ₹ 590.82 crore as compare to the Mar '25 revenue of ₹ 678.63 crore. This represent the decline of -12.94% The revenue of Aarti Pharmalabs Ltd for the Jun '25 is ₹ 387.79 crore as compare to the Mar '25 revenue of ₹ 562.17 crore. This represent the decline of -31.02%.
  • The ebitda of Aarti Drugs Ltd for the Jun '25 is ₹ 74.39 crore as compare to the Mar '25 ebitda of ₹ 95.2 crore. This represent the decline of -21.86% The ebitda of Aarti Pharmalabs Ltd for the Jun '25 is ₹ 95.04 crore as compare to the Mar '25 ebitda of ₹ 144.02 crore. This represent the decline of -34.01%.
  • The net profit of Aarti Drugs Ltd changed from ₹ 47.97 crore to ₹ 53.97 crore over 9 quarters. This represents a CAGR of 5.38% The net profit of Aarti Pharmalabs Ltd changed from ₹ 47.09 crore to ₹ 49.5 crore over 9 quarters. This represents a CAGR of 2.24% .
  • The Dividend Payout of Aarti Drugs Ltd changed from 3.43 % on March 2020 to 5.8 % on March 2025 . This represents a CAGR of 9.15% over 6 yearsThe Dividend Payout of Aarti Pharmalabs Ltd changed from 10.55 % on March 2023 to 17.61 % on March 2025 . This represents a CAGR of 18.62% over 3 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Aarti Drugs Ltd

  • Aarti Drugs Limited (ADL), incorporated in September, 1984 is a prominent manufacturer of APIs, Pharma Intermediates, and Specialty Chemicals.
  • The Company operates as part of the Aarti Group, a conglomerate with a net worth of USD 900 million.
  • With over 50 compounds for Antibiotics, Anti Protozoal, Anti-Inflammatory, Anti-diabetic, Anti Fungal and Cardioprotectant therapeutic segments, the Company has emerged as market leader in APIs.
  • It has a wholly-owned subsidiary called Pinnacle Life Science Private Limited which operates in the field of manufacturing formulations. The Company has two R&D divisions, one in Tarapur and the other in Turbhe, Maharashtra.
  • It has 3 subsidiaries, namely, Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SpA (foreign subsidiary).

About Aarti Pharmalabs Ltd

  • Aarti Pharmachem Limited, formerly known as Aarti Organics Limited, was incorporated as a Public Limited Company in 2019.
  • The Company changed the name from Aarti Organics Limited to Aarti Pharmachem Limited on July 1, 2021.
  • The Company is engaged in manufacturer of Active Pharmaceutical Ingredients (API), Pharmaceutical Intermediates, New Chemical Entities (NCE), and Xanthine derivatives situated in India.
  • It specialise in developing and manufacturing Highly Potent Active Pharmaceutical Ingredients (HPAPIs) critical for various therapeutic segments such as Anti-cancer, Anti-Asthma, Anti-Hypertensive etc. In 2001, the Company commissioned first API manufacturing Unit in Dombivali (Unit 1) and started Xanthine Unit; further it commissioned first API manufacturing Unit 4 in Tarapur for Regulated Markets in 2005; commissioned Caffeine production at Unit 5 with a capacity of 100 Metric Tonnes (MT) per month in 2016.

Aarti Drugs Ltd News Hub

News

Aarti Drugs to convene AGM

Aarti Drugs announced that the 40th Annual General Meeting(AGM) of the company will be hel...

Read more

03 Sep 2025 16:16

News

Aarti Drugs rises after Q1 PAT jumps 62% YoY to Rs 54 cr

Profit before tax (PBT) rose 16.2% YoY to Rs 51.11 crore in Q1 June 2025. EBITDA jumped 12...

Read more

21 Jul 2025 14:06

News

Aarti Drugs to convene board meeting

Aarti Drugs will hold a meeting of the Board of Directors of the Company on 18 July 2025. ...

Read more

16 Jul 2025 10:24

News

Aarti Drugs to convene board meeting

Aarti Drugs will hold a meeting of the Board of Directors of the Company on 6 May 2025. Po...

Read more

30 Apr 2025 11:38

News

Aarti Drugs receives affirmation in credit ratings from ICRA

Aarti Drugs has received reaffirmation in credit rating at ICRA AA-; Stable/ ICRA A1+ for ...

Read more

31 Jan 2025 19:10

News

Aarti Drugs gains as PAT rises to Rs 37 cr in Q3; declares dividend of Re 1/sh

Revenue from operations declined 6.44% to Rs 568.50 crore in third quarter of FY25 as comp...

Read more

30 Jan 2025 12:14

Aarti Pharmalabs Ltd News Hub

News

Aarti Pharmalabs gains on commissioning phase 1 of new Gujarat facility

According to an exchange filing, the company confirmed that it has received all necessary ...

Read more

03 Sep 2025 15:16

News

Aarti Pharmalabs schedules AGM

Aarti Pharmalabs announced that the Annual General Meeting(AGM) of the company will be hel...

Read more

30 Aug 2025 11:24

News

Aarti Pharmalabs slides after Q1 PAT tumbles 11% YoY to Rs 50 cr

Revenue from operations slumped 30.47% YoY to Rs 386.19 crore in the quarter ended 30 June...

Read more

13 Aug 2025 15:38

News

Aarti Pharmalabs to convene board meeting

Aarti Pharmalabs will hold a meeting of the Board of Directors of the Company on 12 August...

Read more

02 Aug 2025 09:51

News

Board of Aarti Pharmalabs recommends final dividend

Aarti Pharmalabs announced that the Board of Directors of the Company at its meeting held ...

Read more

12 May 2025 09:19

News

Aarti Pharmalabs Q4 PAT climbs 35% YoY to Rs 88 cr

Revenue from operations jumped 11.46% YoY to Rs 563.78 crore in the quarter ended 31 March...

Read more

12 May 2025 10:44

SWOT Analysis Of Aarti Pharmalabs Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Aarti Drugs Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Aarti Pharmalabs Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Aarti Drugs Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Aarti Drugs Ltd and Aarti Pharmalabs Ltd

Which company has a larger market capitalization, Aarti Drugs Ltd or Aarti Pharmalabs Ltd?

Market cap of Aarti Drugs Ltd is 4,696 Cr while Market cap of Aarti Pharmalabs Ltd is 8,275 Cr

What are the key factors driving the stock performance of Aarti Drugs Ltd and Aarti Pharmalabs Ltd?

The stock performance of Aarti Drugs Ltd and Aarti Pharmalabs Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aarti Drugs Ltd and Aarti Pharmalabs Ltd?

As of September 11, 2025, the Aarti Drugs Ltd stock price is INR ₹510.85. On the other hand, Aarti Pharmalabs Ltd stock price is INR ₹912.95.

How do dividend payouts of Aarti Drugs Ltd and Aarti Pharmalabs Ltd compare?

To compare the dividend payouts of Aarti Drugs Ltd and Aarti Pharmalabs Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions